Vraylar cariprazine 6 mg Capsule, Gelatin Coated — NDC 70518-3157-0 (Billing 70518-3157-00)
by REMEDYREPACK INC. · 30 POUCH in 1 BOX / 1 CAPSULE, GELATIN COATED in 1 POUCH
This is a package of Vraylar cariprazine 6 mg Capsule, Gelatin Coated from REMEDYREPACK INC., no longer marketed, no longer in the FDA NDC Directory. It is this product's only package size.
NDC 70518-3157-00
🏷️ FDA NDC (as labeled)
70518-3157-0
billing pads the package segment with a zero
🗂️ FDA directory synced Oct 8, 2026 · this listing last changed Jan 19, 2024 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →
NDC database record
One package, one record: these facts belong to NDC 70518-3157-0 alone.
- Record
- FDA NDC Directory package listing · Human prescription drug
- Code segments
- 70518 labeler · 3157 product · 0 package
- Barcode (UPC-A, from the NDC)
- 3 7051831570 6
- FDA record last changed
- Jan 19, 2024
⚠️
Excluded from the active FDA NDC Directory.
The labeler reported this product as discontinued, so it is excluded from the active NDC Directory. The listing was last certified through Jan 2024. A label may still appear on DailyMed, but the NDC is no longer in the current FDA NDC Directory.
Search the FDA NDC Directory ↗
Identity & classification
Regulatory identifiers FDA, NLM and CMS codes for this package
FDA NDC (as labeled)
70518-3157-0
Product NDC
70518-3157
11-digit billing NDC
70518315700
Application #
NDA204370
Established class (EPC)
Atypical Antipsychotic
DEA schedule
Non-controlled
Marketing category
NDA
Marketing status
Discontinued
FDA listing status
Discontinued by firm (certified through Jan 2024)
Route
ORAL
Dosage form
CAPSULE, GELATIN COATED
Substance
CARIPRAZINE
Why two NDCs?
The FDA registers this code as 70518-3157-0 — a 5-4-1 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the package segment → 70518-3157-00. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.
- FDA openFDA NDC Directory · synced Oct 8, 2026
- FDA label on DailyMed · label index refreshed Oct 8, 2026
- RxNorm (NLM RxNav) · catalog refreshed Oct 8, 2026
- Medi-Span GPI (licensed)
- First Databank (licensed) · refreshed Oct 8, 2026
Clinical
📗 Our plain-language guide HelloPharmacist
- Vraylar (cariprazine) is an antipsychotic medication used for a few different conditions. It can treat schizophrenia, the manic or mixed episodes of bipolar I disorder, and the dep...
- What exactly is Vraylar used for? My doctor prescribed it but didn't fully explain.
- This one requires some patience. Vraylar and its active breakdown products stay in your body for a long time, and it can take several weeks for levels to fully build up and stabili...
- How long does it take for Vraylar to start working?
Patient education
Supplement & herbal interactions
Some supplements/herbs that may interact with Cariprazine Hydrochloride — tap one for details:
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.
- MedlinePlus (NLM) · refreshed Oct 8, 2026
- FDA label on DailyMed · label index refreshed Oct 8, 2026
💬 Questions about cariprazine?
Ask a pharmacist →
Ask a licensed pharmacist directly — free, answered by our team.
Pricing
A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.
| Price system | Per each | Per package |
|---|---|---|
| Retail pharmacies payNADAC · weekly | Not in the retail survey — common for institutional, discontinued, or low-volume packs. | |
| Medicaid paysCMS SDUD · 12 mo | No recent Medicaid claims on file for this NDC — rare and low-volume NDCs are suppressed in the public data. | |
| Medicare drug plans payPart D · quarterly | No Part D plan price is available for this NDC in our data. | |
ℹ️
No price is published for this exact package yet. CMS surveys NADAC per package size, so a different pack of the same drug often has one.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.
- CMS NADAC weekly file
- CMS ASP pricing files · refreshed Sep 20, 2026
- CMS Medicaid State Drug Utilization Data · refreshed Oct 9, 2026
- CMS Part D plan pricing files · refreshed Sep 24, 2026
- VA National Acquisition Center price file
Packaging — all sizes for this product
| Package NDC | Description | Marketing start | Marketing end | Status |
|---|---|---|---|---|
| 70518-3157-00 You're viewing this Main listing | 30 POUCH in 1 BOX / 1 CAPSULE, GELATIN COATED in 1 POUCH | 2021-07-15 | — | Discontinued by firm |
Therapeutic equivalents
| Product | Labeler | Pack | NADAC/unit | TE | Status | Price vs. this |
|---|---|---|---|---|---|---|
| Vraylar 6 mgthis 70518-3157-00 | REMEDYREPACK | 1 capsule | — | — | Discontinued | — |
About this product: this is the brand-name version. Some generic versions are approved by the FDA, but we could not confirm current pharmacy availability from our pricing/market data.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.
- FDA openFDA NDC Directory · synced Oct 8, 2026
- FDA Orange Book · refreshed Oct 9, 2026
- CMS NADAC weekly file
Availability & generic status
🏛️
2015
First FDA approval
Sep 2015
📍
2026
Currently FDA-listed
11 years listed
🛡️
2030
Latest patent/protection listed
not a guaranteed launch date
🔒Generic approved by FDA, but pharmacy availability is not confirmed
The FDA lists approved generic versions of this medicine, but that does not always mean a pharmacy can get one today. Patent rules, launch agreements, supply and pricing can affect when generics actually arrive.
🛡️ Latest patent/protection date listed: FDA patent/protection data lists protections through Mar 2030. This may affect when a full generic version becomes widely available, but it is not a guaranteed launch date.
Why the date isn’t exact: Generic timing can change because patents may be challenged, settled, licensed, added, removed, or worked around with a narrower label — and FDA approval does not always mean a pharmacy can get the generic today.
When could a generic Vraylar arrive?
Our estimate: March 2030 about 3.5 years away
How sure: Likely. Firm enough to plan around, but a court ruling or a new deal could still move it.
Why then: The brand company and a generic maker settled their patent fight and agreed on when a generic can launch.
That is before the March 2030 date above, which is common: a court ruling or a deal with the brand’s maker often lets a generic in before the last patent runs out.
See the full forecast for generic Vraylar →Patents & exclusivity — FDA Orange Book
US 7737142 — drug substance (U-2544)
US 7737142 — drug substance (U-2545)
US RE47350 — method of use (U-1750)
US 7737142 — drug substance (U-2545)
US 7737142 — drug substance (U-2544)
US 7737142 — drug substance (U-1750)
US 7737142 — drug substance (U-2543)
US 7737142 — drug substance (U-1750)
US 7737142 — drug substance (U-2543)
US 7737142 — drug substance (U-1750)
US RE47350 — method of use (U-2543)
US 7737142 — drug substance (U-1750)
US 7737142 — drug substance (U-2543)
US 7737142 — drug substance (U-2544)
US 7737142 — drug substance (U-2544)
US RE49110 — method of use (U-2545)
US RE49110 — method of use (U-2544)
US RE49110 — method of use (U-2543)
US RE49110 — method of use (U-2545)
US RE49110 — method of use (U-2543)
US RE49110 — method of use (U-2544)
US RE49110 — method of use (U-2544)
US RE49110 — method of use (U-2543)
US RE49110 — method of use (U-2545)
US RE49110 — method of use (U-2545)
US RE49110 — method of use (U-2544)
US RE49110 — method of use (U-2543)
US 7737142 — drug substance (U-2543)
US 7737142 — drug substance (U-2544)
US 7737142 — drug substance (U-3503)
US 7737142 — drug substance (U-2545)
US 7737142 — drug substance (U-2543)
US 7737142 — drug substance (U-2544)
US 7737142 — drug substance (U-3503)
US 7737142 — drug substance (U-2545)
US RE49110 — method of use (U-2543)
US RE49110 — method of use (U-2544)
US RE49110 — method of use (U-2545)
US RE49110 — method of use (U-3503)
US RE49110 — method of use (U-2545)
US RE49110 — method of use (U-3503)
US RE49110 — method of use (U-2543)
US RE49110 — method of use (U-2544)
US RE47350 — method of use (U-2543)
US RE47350 — method of use (U-2544)
US RE47350 — method of use (U-3503)
US RE47350 — method of use (U-2545)
US RE47350 — method of use (U-2543)
US RE47350 — method of use (U-3503)
US RE47350 — method of use (U-2545)
US RE47350 — method of use (U-2544)
US RE47350 — method of use (U-3503)
US RE49110 — method of use (U-3503)
US 7737142 — drug substance (U-3503)
US 7737142 — drug substance (U-3503)
US RE49110 — method of use (U-3503)
US RE49302 — method of use (U-2543)
US RE49302 — method of use (U-2543)
US RE49302 — method of use (U-2543)
US RE49302 — method of use (U-2543)
US RE49302 — method of use (U-3503)
US RE49302 — method of use (U-2544)
US RE49302 — method of use (U-2545)
US RE49302 — method of use (U-2545)
US RE49302 — method of use (U-2544)
US RE49302 — method of use (U-3503)
US RE49302 — method of use (U-2544)
US RE49302 — method of use (U-3503)
US RE49302 — method of use (U-2545)
US RE49302 — method of use (U-2544)
US RE49302 — method of use (U-2545)
US RE49302 — method of use (U-3503)
US RE47350 — method of use (U-2544)
US RE47350 — method of use (U-2545)
US 7737142 — drug substance (U-2543)
US 7943621 — drug substance
US 7943621 — drug substance
US 7943621 — drug substance
US 7943621 — drug substance
US 7943621 — drug substance
US 7943621 — drug substance
US 7737142*PED — drug product
US 7943621*PED — drug product
US 7943621*PED — drug product
US 7737142*PED — drug product
US 7737142*PED — drug product
US 7943621*PED — drug product
US 7737142*PED — drug product
US 7943621*PED — drug product
US RE47350*PED — drug product
US RE49110*PED — drug product
US RE49110*PED — drug product
US RE47350*PED — drug product
US 7737142*PED — drug product
US 7737142*PED — drug product
US 7943621*PED — drug product
US 7943621*PED — drug product
US RE49302*PED — drug product
US RE49302*PED — drug product
US RE49302*PED — drug product
US RE49302*PED — drug product
US RE49110*PED — drug product
US RE49110*PED — drug product
US RE49110*PED — drug product
US RE49110*PED — drug product
US RE47350*PED — drug product
Exclusivity M-14
Exclusivity NPP
Exclusivity M-14
Exclusivity NPP
Exclusivity M-14
Exclusivity NPP
Exclusivity M-14
Exclusivity M-14
Exclusivity NPP
Exclusivity M-14
Exclusivity NPP
Exclusivity PED
Exclusivity PED
Exclusivity PED
Exclusivity PED
Exclusivity PED
Exclusivity PED
Exclusivity PED
Exclusivity PED
Exclusivity PED
Exclusivity PED
Exclusivity PED
2015
2017
2019
2021
2023
2025
2027
2029
Substance patent
Formulation patent
Method-of-use patent
Exclusivity
Pediatric +6mo
🏛️FDA exclusivity
FDA-granted marketing protection. It’s separate from patents and may be shorter than patent protection.
🧪Product / substance patents
Patents covering the active ingredient, product, formulation, or related drug features.
🎯Method-of-use patents
Patents covering specific approved uses. These can sometimes be carved out with a “skinny label,” but not always.
🛈 What do these terms mean?
- Patent
- Legal protection listed in the Orange Book that may delay generic approval or launch. Issued by the U.S. Patent & Trademark Office.
- Substance patent
- Covers the active drug molecule itself — the hardest to design around. A generic generally can’t launch until it expires.
- Formulation (product) patent
- Covers a specific formulation or dosage form. A generic can sometimes work around it with a different formulation.
- Method-of-use patent
- A patent covering one specific approved use of the drug — not necessarily the whole molecule. A generic can sometimes launch with a “skinny label” that carves out the protected use and keeps the others.
- Skinny label
- A generic label that omits a still-patented use when the FDA allows it — letting a generic reach the market for the unprotected uses.
- Exclusivity
- FDA-granted marketing protection, separate from patents — e.g. 5-yr new chemical entity, 7-yr orphan drug, or a +6-month pediatric extension.
- Paragraph IV
- A generic applicant’s formal challenge to a listed patent. It can potentially lead to earlier generic entry, but often involves litigation or a settlement.
- RLD / RS
- Reference Listed Drug — the brand product the FDA uses as the reference for generic applications. Reference Standard — the product the FDA expects generics to compare against in bioequivalence testing.
- TE / AB rating
- FDA therapeutic-equivalence rating. An AB rating generally means the FDA considers a generic therapeutically equivalent to — and substitutable for — the brand.
- LOE (loss of exclusivity)
- The latest patent or exclusivity currently listed — the loss-of-exclusivity / latest-listed-protection date shown on this page. Paragraph-IV challenges and settlements can move the real date earlier; FDA approval and a manufacturer’s decision to market can move it later.
Built from the FDA Orange Book. The bars above are scaled to each protection’s expiry; the red LOE marker is the last one to lapse.
Listed patents (106)
| Patent | Type | Use code | Expires |
|---|---|---|---|
| US 7737142 ↗ | Drug substance | U-2544 | Sep 17, 2029 |
| US 7737142 ↗ | Drug substance | U-2545 | Sep 17, 2029 |
| US RE47350 ↗ | Method of use | U-1750 | Jul 16, 2029 |
| US 7737142 ↗ | Drug substance | U-2545 | Sep 17, 2029 |
| US 7737142 ↗ | Drug substance | U-2544 | Sep 17, 2029 |
| US 7737142 ↗ | Drug substance | U-1750 | Sep 17, 2029 |
| US 7737142 ↗ | Drug substance | U-2543 | Sep 17, 2029 |
| US 7737142 ↗ | Drug substance | U-1750 | Sep 17, 2029 |
| US 7737142 ↗ | Drug substance | U-2543 | Sep 17, 2029 |
| US 7737142 ↗ | Drug substance | U-1750 | Sep 17, 2029 |
| US RE47350 ↗ | Method of use | U-2543 | Jul 16, 2029 |
| US 7737142 ↗ | Drug substance | U-1750 | Sep 17, 2029 |
| US 7737142 ↗ | Drug substance | U-2543 | Sep 17, 2029 |
| US 7737142 ↗ | Drug substance | U-2544 | Sep 17, 2029 |
| US 7737142 ↗ | Drug substance | U-2544 | Sep 17, 2029 |
| US RE49110 ↗ | Method of use | U-2545 | Jul 16, 2029 |
| US RE49110 ↗ | Method of use | U-2544 | Jul 16, 2029 |
| US RE49110 ↗ | Method of use | U-2543 | Jul 16, 2029 |
| US RE49110 ↗ | Method of use | U-2545 | Jul 16, 2029 |
| US RE49110 ↗ | Method of use | U-2543 | Jul 16, 2029 |
| US RE49110 ↗ | Method of use | U-2544 | Jul 16, 2029 |
| US RE49110 ↗ | Method of use | U-2544 | Jul 16, 2029 |
| US RE49110 ↗ | Method of use | U-2543 | Jul 16, 2029 |
| US RE49110 ↗ | Method of use | U-2545 | Jul 16, 2029 |
| US RE49110 ↗ | Method of use | U-2545 | Jul 16, 2029 |
| US RE49110 ↗ | Method of use | U-2544 | Jul 16, 2029 |
| US RE49110 ↗ | Method of use | U-2543 | Jul 16, 2029 |
| US 7737142 ↗ | Drug substance | U-2543 | Sep 17, 2029 |
| US 7737142 ↗ | Drug substance | U-2544 | Sep 17, 2029 |
| US 7737142 ↗ | Drug substance | U-3503 | Sep 17, 2029 |
| US 7737142 ↗ | Drug substance | U-2545 | Sep 17, 2029 |
| US 7737142 ↗ | Drug substance | U-2543 | Sep 17, 2029 |
| US 7737142 ↗ | Drug substance | U-2544 | Sep 17, 2029 |
| US 7737142 ↗ | Drug substance | U-3503 | Sep 17, 2029 |
| US 7737142 ↗ | Drug substance | U-2545 | Sep 17, 2029 |
| US RE49110 ↗ | Method of use | U-2543 | Jul 16, 2029 |
| US RE49110 ↗ | Method of use | U-2544 | Jul 16, 2029 |
| US RE49110 ↗ | Method of use | U-2545 | Jul 16, 2029 |
| US RE49110 ↗ | Method of use | U-3503 | Jul 16, 2029 |
| US RE49110 ↗ | Method of use | U-2545 | Jul 16, 2029 |
| US RE49110 ↗ | Method of use | U-3503 | Jul 16, 2029 |
| US RE49110 ↗ | Method of use | U-2543 | Jul 16, 2029 |
| US RE49110 ↗ | Method of use | U-2544 | Jul 16, 2029 |
| US RE47350 ↗ | Method of use | U-2543 | Jul 16, 2029 |
| US RE47350 ↗ | Method of use | U-2544 | Jul 16, 2029 |
| US RE47350 ↗ | Method of use | U-3503 | Jul 16, 2029 |
| US RE47350 ↗ | Method of use | U-2545 | Jul 16, 2029 |
| US RE47350 ↗ | Method of use | U-2543 | Jul 16, 2029 |
| US RE47350 ↗ | Method of use | U-3503 | Jul 16, 2029 |
| US RE47350 ↗ | Method of use | U-2545 | Jul 16, 2029 |
| US RE47350 ↗ | Method of use | U-2544 | Jul 16, 2029 |
| US RE47350 ↗ | Method of use | U-3503 | Jul 16, 2029 |
| US RE49110 ↗ | Method of use | U-3503 | Jul 16, 2029 |
| US 7737142 ↗ | Drug substance | U-3503 | Sep 17, 2029 |
| US 7737142 ↗ | Drug substance | U-3503 | Sep 17, 2029 |
| US RE49110 ↗ | Method of use | U-3503 | Jul 16, 2029 |
| US RE49302 ↗ | Method of use | U-2543 | Jul 16, 2029 |
| US RE49302 ↗ | Method of use | U-2543 | Jul 16, 2029 |
| US RE49302 ↗ | Method of use | U-2543 | Jul 16, 2029 |
| US RE49302 ↗ | Method of use | U-2543 | Jul 16, 2029 |
| US RE49302 ↗ | Method of use | U-3503 | Jul 16, 2029 |
| US RE49302 ↗ | Method of use | U-2544 | Jul 16, 2029 |
| US RE49302 ↗ | Method of use | U-2545 | Jul 16, 2029 |
| US RE49302 ↗ | Method of use | U-2545 | Jul 16, 2029 |
| US RE49302 ↗ | Method of use | U-2544 | Jul 16, 2029 |
| US RE49302 ↗ | Method of use | U-3503 | Jul 16, 2029 |
| US RE49302 ↗ | Method of use | U-2544 | Jul 16, 2029 |
| US RE49302 ↗ | Method of use | U-3503 | Jul 16, 2029 |
| US RE49302 ↗ | Method of use | U-2545 | Jul 16, 2029 |
| US RE49302 ↗ | Method of use | U-2544 | Jul 16, 2029 |
| US RE49302 ↗ | Method of use | U-2545 | Jul 16, 2029 |
| US RE49302 ↗ | Method of use | U-3503 | Jul 16, 2029 |
| US RE47350 ↗ | Method of use | U-2544 | Jul 16, 2029 |
| US RE47350 ↗ | Method of use | U-2545 | Jul 16, 2029 |
| US 7737142 ↗ | Drug substance | U-2543 | Sep 17, 2029 |
| US 7943621 ↗ | Drug substance | — | Dec 20, 2028 |
| US 7943621 ↗ | Drug substance | — | Dec 16, 2028 |
| US 7943621 ↗ | Drug substance | — | Dec 16, 2028 |
| US 7943621 ↗ | Drug substance | — | Dec 20, 2028 |
| US 7943621 ↗ | Drug substance | — | Dec 16, 2028 |
| US 7943621 ↗ | Drug substance | — | Dec 16, 2028 |
| US 7737142*PED ↗ | Drug product | — | Mar 17, 2030 |
| US 7943621*PED ↗ | Drug product | — | Jun 16, 2029 |
| US 7943621*PED ↗ | Drug product | — | Jun 16, 2029 |
| US 7737142*PED ↗ | Drug product | — | Mar 17, 2030 |
| US 7737142*PED ↗ | Drug product | — | Mar 17, 2030 |
| US 7943621*PED ↗ | Drug product | — | Jun 16, 2029 |
| US 7737142*PED ↗ | Drug product | — | Mar 17, 2030 |
| US 7943621*PED ↗ | Drug product | — | Jun 16, 2029 |
| US RE47350*PED ↗ | Drug product | — | Jan 16, 2030 |
| US RE49110*PED ↗ | Drug product | — | Jan 16, 2030 |
| US RE49110*PED ↗ | Drug product | — | Jan 16, 2030 |
| US RE47350*PED ↗ | Drug product | — | Jan 16, 2030 |
| US 7737142*PED ↗ | Drug product | — | Mar 17, 2030 |
| US 7737142*PED ↗ | Drug product | — | Mar 17, 2030 |
| US 7943621*PED ↗ | Drug product | — | Jun 20, 2029 |
| US 7943621*PED ↗ | Drug product | — | Jun 20, 2029 |
| US RE49302*PED ↗ | Drug product | — | Jan 16, 2030 |
| US RE49302*PED ↗ | Drug product | — | Jan 16, 2030 |
| US RE49302*PED ↗ | Drug product | — | Jan 16, 2030 |
| US RE49302*PED ↗ | Drug product | — | Jan 16, 2030 |
| US RE49110*PED ↗ | Drug product | — | Jan 16, 2030 |
| US RE49110*PED ↗ | Drug product | — | Jan 16, 2030 |
| US RE49110*PED ↗ | Drug product | — | Jan 16, 2030 |
| US RE49110*PED ↗ | Drug product | — | Jan 16, 2030 |
| US RE47350*PED ↗ | Drug product | — | Jan 16, 2030 |
FDA exclusivity
| Code | What it grants | Expires |
|---|---|---|
| M-14 | New indication / labeling change (3-year) | Dec 18, 2028 |
| NPP | New Patient Population | Dec 18, 2028 |
| M-14 | New indication / labeling change (3-year) | Dec 18, 2028 |
| NPP | New Patient Population | Dec 18, 2028 |
| M-14 | New indication / labeling change (3-year) | Dec 18, 2028 |
| NPP | New Patient Population | Dec 18, 2028 |
| M-14 | New indication / labeling change (3-year) | Dec 18, 2028 |
| M-14 | New indication / labeling change (3-year) | Dec 18, 2028 |
| NPP | New Patient Population | Dec 18, 2028 |
| M-14 | New indication / labeling change (3-year) | Dec 18, 2028 |
| NPP | New Patient Population | Dec 18, 2028 |
| PED | Pediatric Exclusivity (+6 months) | Jun 18, 2029 |
| PED | Pediatric Exclusivity (+6 months) | Jun 18, 2029 |
| PED | Pediatric Exclusivity (+6 months) | Jun 18, 2029 |
| PED | Pediatric Exclusivity (+6 months) | Jun 18, 2029 |
| PED | Pediatric Exclusivity (+6 months) | Jun 18, 2029 |
| PED | Pediatric Exclusivity (+6 months) | Jun 18, 2029 |
| PED | Pediatric Exclusivity (+6 months) | Jun 18, 2029 |
| PED | Pediatric Exclusivity (+6 months) | Jun 18, 2029 |
| PED | Pediatric Exclusivity (+6 months) | Jun 18, 2029 |
| PED | Pediatric Exclusivity (+6 months) | Jun 18, 2029 |
| PED | Pediatric Exclusivity (+6 months) | Jun 18, 2029 |
Common questions
Is there a generic version of this drug?
Yes — an FDA-approved generic equivalent is listed in the FDA Orange Book for this drug. See the alternatives section for substitutable, lower-cost products. An approval does not always mean it is on pharmacy shelves yet: we expect the first generic Vraylar in March 2030, about 3.5 years away. See the forecast.
The FDA approved a generic — why can’t I get it at my pharmacy yet?
FDA approval and pharmacy availability are two different things. The FDA can approve a generic years before it actually reaches pharmacies, because the brand company may still hold patents or have a settlement that delays the launch. A manufacturer also has to choose to make and sell it, and have supply ready. So a drug can be “FDA-approved generic exists” and still be brand-only at the counter today.
Why do different websites show different generic release dates?
Generic availability is not based on one single date. Some sources use the first exclusivity expiration, some use the last product patent, and others use the latest method-of-use patent. Patent challenges, settlements, licenses, and label carve-outs can also change the real-world launch date. This page shows the underlying Orange Book dates so you can see why estimates may differ.
What does “FDA listed” mean?
It means the product appears in the FDA’s official NDC directory. That’s a good sign a product exists and is intended for the U.S. market, but on its own it does not confirm a pharmacy can fill it today. Where we have recent retail pricing data (NADAC) for a product, we label it “Availability likely” instead.
What does a patent or protection date mean here?
It’s the latest date currently listed in the FDA Orange Book for a patent or exclusivity on the brand product. It can affect when a full generic version becomes widely available — but it is not a guaranteed generic launch date. Generics sometimes arrive earlier (through a settlement or patent challenge) or later (a manufacturer still has to make and sell one).
What does “current Orange Book estimate” mean?
It means we are using the latest patent and exclusivity dates currently listed in the FDA Orange Book. It is not a guaranteed launch date.
Can a generic come out before the last patent expires?
Sometimes. A generic company may challenge a patent, settle with the brand manufacturer, receive a license, or obtain approval with a narrower label that avoids a patented use. In other cases, the last listed protection may delay full-label generic competition.
Can a generic come out after the listed dates?
Yes. Even after patents or exclusivity expire, a generic still needs FDA approval and a manufacturer must choose to market it. Supply, litigation, business decisions, or regulatory issues can delay actual availability.
What is the difference between patents and exclusivity?
Patents are legal protections usually issued by the U.S. Patent and Trademark Office. FDA exclusivity is marketing protection granted by the FDA. They are separate, and either one can affect generic timing.
Why are there multiple patent dates?
One drug can have several patents covering different things: the active ingredient, a formulation, a manufacturing process, or a specific approved use. That is why a page may show several expiration dates instead of one simple generic date.
Built from FDA Orange Book patent and exclusivity data. Dates are refreshed from public FDA data when available; the marker is max(latest patent expiry, latest exclusivity expiry). Paragraph-IV settlements and first-filer 180-day exclusivity can shift the real date; a method-of-use patent may allow an earlier skinny-label generic for non-protected indications. Generic launch timing is an estimate, not a guarantee.
Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.
- FDA Orange Book · refreshed Oct 9, 2026
Inactive Ingredients / Excipients
Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.
🧪 Avoiding an ingredient? See Cariprazine inactive ingredients by manufacturer: every current product's list side by side, so you can ask your pharmacy for the version that does not list it.
Loading inactive ingredients from the official FDA label in the background. No external source is being called by this page request.
Where does this data come from?
Source: official FDA Structured Product Labeling (SPL) via DailyMed and the openFDA label index. Structured
IACT rows and label-wide narrative are kept separate; availability and product-level specificity depend on the submitted label.- FDA label on DailyMed · label index refreshed Oct 8, 2026
- FDA openFDA NDC Directory · synced Oct 8, 2026
Inactive ingredient FAQ
Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.
Manufacturer & labeler
LabelerREMEDYREPACK INC.
Application holderABBVIE INC
FDA applicationNDA204370 (NDA)
Labeler code70518
Product typeHuman Prescription Drug
Portfolio1,529 products on file
More NDCs from REMEDYREPACK INC. labeler code 70518
- Metformin Hydrochloride 1000 mg Tablet, Film Coated NDC 70518-3130-0
- Montelukast 10 mg Tablet, Film Coated NDC 70518-3133-0
- metoprolol succinate 25 mg Tablet, Extended Release NDC 70518-3143-0
- Clonazepam 1 mg Tablet NDC 70518-3144-0
- Carbamazepine 200 mg Tablet NDC 70518-3146-0
- Levothyroxine sodium 88 ug Tablet NDC 70518-3154-0
- Potassium Citrate 10 meq Tablet, Extended Release NDC 70518-3160-0
- clonidine hydrochloride .1 mg Tablet NDC 70518-3162-0
- metoprolol succinate 50 mg Tablet, Extended Release NDC 70518-3164-0
- Lisinopril 40 mg Tablet NDC 70518-3166-0
- Azithromycin Dihydrate 500 mg Tablet, Film Coated NDC 70518-3168-0
- Ibuprofen 800 mg Tablet, Film Coated NDC 70518-3178-0
The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.
- FDA openFDA NDC Directory · synced Oct 8, 2026
- Drugs@FDA
Full prescribing information FDA SPL
The complete FDA label for this product — the official prescribing information, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
📄 FDA label ▾
No FDA label is on file for this product yet. Labels load from openFDA / DailyMed and refresh weekly.
No label section mentions that — try another word, or open the full label on DailyMed below.
Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA.
Medicare Part D spend CMS · PART D · 2026 (Q1)
Medicare Part D (outpatient prescription) spending for Vraylar — the program that covers self-administered drugs. 2 manufacturers.
⚠️ Drug-level data: CMS publishes Part D spending by drug, not by NDC — these figures combine every manufacturer, strength and package size sold under the name Vraylar. That’s a different level of aggregation than the Medicaid card above, which is specific to this exact 11-digit NDC (pack size included), so the two aren’t directly comparable.
Period
Total Part D spend
$328.87M
Claims incl. refills
210.8K
Beneficiaries
85.9K
Spend / beneficiary
$3,830.57
Spend / claim
$1,559.86
Trend by period
💵 About the dollar figures: spending is what Part D plans paid before confidential manufacturer rebates, so the program’s real net cost is lower. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part D Spending by Drug (data.cms.gov), updated quarterly.
Reported adverse events (FAERS)
Read carefully: FAERS reports are voluntary and unverified. Counts are not incidence, do not establish causation, are subject to reporting bias, and cannot be used to compare one drug to another. Shown for signal context only. Reports for Vraylar (this brand).
Top reported reactions
Age at onset
Reporter sex
Male · 33%
Female · 67%
Unknown · 0%
Serious outcomes
Reports over time (by year) — tap or hover for the count & year
Most recent year is provisional (FAERS lags ~3 months).
Where does this data come from?
Adverse-event reports from the FDA Adverse Event Reporting System (FAERS) via openFDA. FAERS reports are voluntary and unverified — counts are not incidence and don’t establish causation.
About this NDC listing & data coverage
Finished prescription product
No longer marketed (per FDA listing data)
What data is (and isn’t) available for this NDC — tap to expand
| NDC identity (package / product / labeler codes) | ✓ Available |
| Labeler | ✓ Available |
| Product & package description | ✓ Available |
| Marketing category & status | ✓ Available |
| Active ingredient / dosage form / route | ✓ Available |
| FDA label (SPL via DailyMed) | — Not published for this NDC No structured label is linked to this listing in DailyMed/openFDA. |
| Package photos | — Not published for this NDC No photo available yet for this listing. |
| Inactive ingredients (structured) | — Not published for this NDC The labeler did not submit a structured excipient list, or no SPL is available. |
| NADAC pharmacy acquisition price (CMS) | — Not published for this NDC CMS publishes NADAC only for NDCs reported in its retail-pharmacy survey. |
| Orange Book / therapeutic-equivalence data | ✓ Available |
| HCPCS J-code billing crosswalk | — Not published for this NDC Most self-administered / retail products have no J-code — that is normal. |
| Medicaid utilization (CMS SDUD) | — Not published for this NDC CMS reports utilization only for NDCs with Medicaid claims above its privacy threshold. |
“Not published” reflects what the public FDA / CMS / NLM sources provide for this exact package code — it is a property of the data feeds, not a judgment about the product.
Questions about this listing
Why is there no price listed?
The pricing shown on our NDC pages comes from CMS NADAC, a voluntary survey of retail community pharmacy invoices. CMS does not publish a NADAC for every NDC — packages outside the retail survey (institutional and hospital products, bulk packages, discontinued items, and many OTC items) may never receive one. A missing price reflects the survey's scope, not this product's actual cost, and does not mean the product is free or unavailable.
Why is there no full label on this page?
No structured FDA label (SPL) is currently linked to this NDC in DailyMed/openFDA. That can happen with older listings, certain OTC and repackaged products, and recently updated listings whose label has not yet propagated. The listing itself is still valid — this page shows everything the public feeds provide for this package.
What does the discontinued status mean for this NDC?
The labeler reported a marketing end date (or the listing was delisted), so this specific package is no longer actively marketed. Remaining stock may still be dispensed for a time, and the NDC stays valid for historical records and claims — but data feeds (pricing, labeling) typically stop updating for it. Other package sizes or other manufacturers' versions of the same medication may still be marketed — see the equivalents section where available.
Is the NDC printed on the package the same as the 11-digit billing NDC?
Yes, they identify this exact package in different formats. The form printed on the packaging and shown on DailyMed is the one the FDA registered. Insurance claims use a fixed 11-digit 5-4-2 format, so the short segment is padded with a leading zero and the dashes are dropped. The Identity section at the top of this page lists each form of this code.
Who lists this product with the FDA?
REMEDYREPACK INC. is the labeler of record for this NDC — the company under whose FDA-assigned code the package is listed. The labeler may be the manufacturer itself or a distributor marketing the product under its own code.
Do I need a prescription for this product?
This NDC is listed with FDA as a prescription product, so it is dispensed under a prescriber's order. Your pharmacist can tell you whether any over-the-counter forms of the same medication exist.
This page identifies an FDA-listed package (the NDC) and reports public regulatory and pricing data about the listing. It is reference information, not a medical recommendation — talk to your pharmacist or prescriber about your own medication.
Where does this data come from?
Listing facts (marketing category, packager status, marketing dates) from the FDA openFDA NDC Directory; label availability from DailyMed; pricing coverage from CMS NADAC; equivalence scope from the FDA Orange Book.
For educational and professional reference only — not medical advice. Pricing reflects published
NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.